- Home
- RTX vs ABBV Comparison
RTX vs ABBV Comparison
Compare RTX & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RTX | ABBV |
|---|---|---|
| Founded | 1934 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.4B | 451.5B |
| IPO Year | 1994 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RTX | ABBV |
|---|---|---|
| Price | $191.23 | $284.98 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 30 |
| Target Price | $227.78 | ★ $282.61 |
| AVG Volume (30 Days) | ★ 4.2M | 3.2M |
| Earning Date | 10-20-2026 | 10-30-2026 |
| Dividend Yield | 1.50% | ★ 2.43% |
| EPS Growth | ★ 39.72 | N/A |
| EPS | ★ 4.96 | 2.42 |
| Revenue | ★ $80,738,000,000.00 | $61,160,000,000.00 |
| Revenue This Year | $8.54 | $10.57 |
| Revenue Next Year | $7.53 | $8.79 |
| P/E Ratio | ★ $39.17 | $117.54 |
| Revenue Growth | ★ 17.15 | 8.57 |
| 52 Week Low | $166.74 | $190.75 |
| 52 Week High | $226.88 | $291.40 |
Technical Indicators
Market Signals| Indicator | RTX | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 50.10 | 64.68 |
| Support Level | $171.54 | $204.45 |
| Resistance Level | $205.11 | $291.40 |
| Average True Range (ATR) | 4.56 | 6.86 |
| MACD | 1.55 | 0.65 |
| Stochastic Oscillator | 67.32 | 79.73 |
Price Performance
Historical ComparisonAbout RTX RTX Corporation
RTX is an aerospace and defense manufacturer formed from the merger of United Technologies and Raytheon, with roughly equal exposure across three segments, mostly as a supplier to commercial aerospace and to the defense market: Collins Aerospace, a diversified aerospace supplier; Pratt & Whitney, a commercial and military aircraft engine manufacturer; and Raytheon, a defense prime contractor providing a mix of missiles, missile defense systems, sensors, hardware, and communications technology to the military.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.